Actinogen Medical Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Actinogen Medical şirketinin kazançlarının yıllık 22.1% oranında düşmesi, yıllık gelirinin ise yıllık 20% oranında artması bekleniyor. EPS'nin yıllık 0.01% oranında düşüşmesi bekleniyor.

Anahtar bilgiler

-22.1%

Kazanç büyüme oranı

-0.009%

EPS büyüme oranı

Biotechs kazanç büyümesi	15.3%
Gelir büyüme oranı	20.0%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	31 Oct 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

CHIA:ACW - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2026	14	-20	-13	N/A	1
6/30/2025	7	-12	-9	N/A	1
6/30/2024	10	-13	-17	-17	N/A
3/31/2024	7	-14	-15	-15	N/A
12/31/2023	5	-15	-13	-13	N/A
9/30/2023	5	-13	-11	-11	N/A
6/30/2023	5	-11	-9	-9	N/A
3/31/2023	5	-11	-9	-9	N/A
12/31/2022	5	-11	-9	-9	N/A
9/30/2022	4	-10	-9	-9	N/A
6/30/2022	4	-9	-10	-10	N/A
3/31/2022	3	-8	-8	-8	N/A
12/31/2021	2	-7	-6	-6	N/A
9/30/2021	2	-6	-4	-4	N/A
6/30/2021	2	-4	-2	-2	N/A
3/31/2021	2	-4	-2	-2	N/A
12/31/2020	3	-4	-2	-2	N/A
9/30/2020	3	-4	-3	-3	N/A
6/30/2020	4	-5	-3	-3	N/A
3/31/2020	5	-6	-5	-5	N/A
12/31/2019	6	-7	-7	-7	N/A
9/30/2019	5	-8	-9	-9	N/A
6/30/2019	5	-10	-10	-10	N/A
3/31/2019	4	-10	-10	-10	N/A
12/31/2018	3	-10	-9	-9	N/A
9/30/2018	3	-8	-8	-8	N/A
6/30/2018	3	-6	-8	-8	N/A
3/31/2018	2	-6	N/A	-6	N/A
12/31/2017	2	-5	N/A	-4	N/A
9/30/2017	1	-4	N/A	-3	N/A
6/30/2017	1	-3	N/A	-1	N/A
3/31/2017	2	-4	N/A	-2	N/A
12/31/2016	3	-4	N/A	-2	N/A
9/30/2016	3	-4	N/A	-4	N/A
6/30/2016	4	-4	N/A	-5	N/A
3/31/2016	3	-5	N/A	-5	N/A
12/31/2015	1	-5	N/A	-5	N/A
9/30/2015	1	-5	N/A	-4	N/A
6/30/2015	0	-5	N/A	-4	N/A
3/31/2015	0	-3	N/A	-2	N/A
12/31/2014	0	-2	N/A	-1	N/A
9/30/2014	0	-1	N/A	-1	N/A
6/30/2014	0	0	N/A	0	N/A
3/31/2014	0	0	N/A	0	N/A
12/31/2013	0	0	N/A	0	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ACW önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: ACW önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: ACW önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: ACW şirketinin gelirinin (yıllık 20% ) Australian pazarından (yıllık 5.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ACW şirketinin gelirinin (yıllık 20% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ACW 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Actinogen Medical Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Actinogen Medical Appoints Andrew Udell as Chief Commercial Officer

Actinogen Medical Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Actinogen Medical Limited, Annual General Meeting, Nov 14, 2024

New major risk - Revenue and earnings growth

Actinogen Medical Limited Announces Further Positive Results on Depression in the XanCIDD Phase 2A Trial

Actinogen Medical Limited as Announces Achievement of Clinically and Statically Significant Superiority of Xanamem over Placebo on Depression in Xanacidd Phase 2A Trial

New minor risk - Market cap size

Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker

New major risk - Revenue and earnings growth

Actinogen Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.

Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial

Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial

Actinogen Medical Limited Announces CFO Changes

AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston

Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results

New minor risk - Shareholder dilution

Actinogen Medical Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

New major risk - Financial position

Actinogen Medical Limited to Present Progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 Trials at the BIO International Convention

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Ltd Announces Receipt of Agreement from US Food and Drug Administration Agrees to Six-Month Phase 2b Alzheimers Disease Trial

Actinogen Medical Limited Announces First Patient Treated in Depression and Cognitive Impairment Phase 2 Clinical Trial

Actinogen Medical Limited Announces First Patient Treated in XanaCIDD Phase 2 Depression Trial

MD, CEO & Director recently bought AU$94k worth of stock

Actinogen Medical Limited Announces Positive Alzheimers Disease Clinical Results

Actinogen Medical Limited, Annual General Meeting, Nov 16, 2022

Actinogen Medical Limited Announces Phase 2 Trials in Alzheimer's Disease and Depression

Actinogen Medical Limited Announces Phase 2 Trial Designs for AD & MDD

MD, CEO & Director recently bought AU$128k worth of stock

Actinogen Medical Limited Announces Positive XanaMIA Results for Xanamem

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Expects Top-Line Results for the XanaMIA Part A Trial to Be Available in April 1

Actinogen Medical Announces Enrolment Reach in the XanaMIA Part A Trial of 105 Participants

Actinogen Medical Limited Completes Global Patent Family Grant

Actinogen Medical Limited Announces First Patient Enrolled in XanaMIA Trial

Actinogen Receives Positive Pre-IND FDA Advice for FXS

Actinogen Medical Receives Ethics Committee Approval for XanaMIA study

Actinogen Medical Limited Appoints Steven Gourlay as CEO

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Wins FDA Actinogen's Drug Xanamem Rare Paediatric Disease Designation for the Treatment of Fragile X Syndrome

Actinogen Medical Limited Announces Two New Clinical Trials

Actinogen Medical Limited Appoints Jeff Carter as Chief Financial Officer

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin